Rare Disease Spotlight: Hemophilia Treatment Advances
Pricing: Free for Members and Non-Members
This activity is supported by an educational grant from CSL Behring.
Course Description
Currently, about 20,000 individuals are living with hemophilia in the United States, and about 60% of individuals with hemophilia A experience a severe form of the blood disorder. Those with hemophilia B, however, might not begin exhibiting symptoms until later in life. Development in the rare disease drug landscape is expected to increase, where one-third of the drug pipeline extending to 2024 is through the orphan drug approval pathway. The first hemophilia B gene therapy received FDA approval in November 2022 and additional novel hemophilia treatment options are expected within the next year—what managed care strategies reduce treatment gaps and address unmet needs? Faculty for this session will discuss hemophilia treatment advances, identify considerations for developing payment models, and discuss innovative methods to address access to care.
Target Audience
Pharmacists who practice in managed care settings.
Learning Objectives
At the completion of this activity, participants should be able to
- Review the incidence, current treatment options, and pipeline for hemophilia, a rare blood disorder.
- Identify managed care considerations for developing payment models for hemophilia.
- Discuss innovative methods to address access to care for the rare blood disease hemophilia and emerging durable cure treatments
Faculty
Jessica Naber, FSA, MAAA
Principal and Consulting Actuary
Milliman, Inc.
Indianapolis, IN
Guy Young, MD
Director, Hemostasis and Thrombosis Center
Children's Hospital Los Angeles
Hermosa Beach, CA
Moderator
Renee Rizzo, RPh, MBA
President
PRN Managed Care Consulting Services, LLC
East Amherst, New York
Financial Relationship Disclosures
Faculty/Reviewer/Planner | Reported Relevant Financial Relationships |
Jessica Naber Faculty | Disclosed no relevant financial relationships. |
Guy Young Faculty | Consultant: CSL Behring, BioMarin, Sanofi, Pfizer, Novo Nordisk |
Susanne Dudash | Employee: Express Scripts |
Jennifer Evans Planner | Disclosed no relevant financial relationships. |
- AMCP Staff have disclosed no relevant financial relationships.
- If applicable, relevant financial relationships have been mitigated and documented.
- Content has undergone a peer review to ensure content validity.
Accreditation:
The Academy of Managed Care Pharmacy (AMCP) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
ACPE UAN:0233-0000-23-008-H03-P • Activity Type: Knowledge-Based
Contact Hours: 1.25
Release Date: March 23, 2023 • Expiration Date: December 31, 2024
Activity Fee: Free for Members and $30 for Non-Members
Participants should claim continuing pharmacy education (CPE) credit for this home study activity only if they have not claimed credit for the live activity presented at AMCP 2023. CPE credit will be processed through the AMCP Learn portal and reported directly to CPE Monitor. Please allow 72 hours for processing and posting in your NABP account.
To receive credit for an online activity you must:
- Review the full content of the activity.
- Successfully complete the post-test (required to pass with a score of 70% or higher, it may be taken a maximum of three times).
- Complete a specific activity evaluation.
Available Credit
- 1.25 ACPEThe Academy of Managed Care Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
- 1.25 Certificate of Completion
Price
Required Hardware/software
System Requirements Courses and learning activities are delivered via your Web browser and Acrobat PDF. For all activities, you should have a basic comfort level using a computer and navigating websites. View the minimum technical and system requirements for continuing education online learning activities